PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 122 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency MOST POPULAR ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ ΑΔΕΝΑ July 22, 2019 Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... July 29, 2025 EMA Recommends Granting a Marketing Authorisation for Sugemalimab June 21, 2024 Strengthening EU Support for Rare Cancers under the 2028–2034 Multiannual Financial... November 17, 2025 Load more HOT NEWS Government update on the Clinical Research Vision: More needed to go... Cancer in My Community: Improving Access to Palliative Care in Indonesia “No Person With Cancer or Survivor Should Ever Feel Alone”: A... 2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal...
